Last reviewed · How we verify
Anti-diabetic medications
Anti-diabetic medications work through various mechanisms to lower blood glucose levels by enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.
Anti-diabetic medications work through various mechanisms to lower blood glucose levels by enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (insulin-based therapies).
At a glance
| Generic name | Anti-diabetic medications |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Anti-diabetic agents (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Anti-diabetic medications represent a broad class of drugs with multiple distinct mechanisms of action. These include insulin secretagogues (stimulating pancreatic beta cells), biguanides (reducing hepatic glucose output), thiazolidinediones (improving peripheral insulin sensitivity), DPP-4 inhibitors (prolonging incretin action), GLP-1 agonists (enhancing glucose-dependent insulin secretion), and SGLT2 inhibitors (promoting urinary glucose excretion). The specific mechanism depends on the individual drug within this class.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus (insulin-based therapies)
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (metformin)
- Urinary tract infections (SGLT2 inhibitors)
Key clinical trials
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Drug-coated Balloons and Drug-eluting Stents in Diabetic Patients
- Anti-Diabetic Medications to Fight PD and LBD (PHASE4)
- Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-diabetic medications CI brief — competitive landscape report
- Anti-diabetic medications updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI